Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma

Hsiang, Walter; Kenney, Patrick A.; Leapman, Michael

doi:10.1007/s11912-020-0895-y

Cited by 5 publications

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…At present, there is still controversy about the specific regimen of the combination of systemic therapies and local therapies. Most researchers consider that local therapies should be used after systemic therapies (31,32). On the one hand, great progress has been made in systemic Some metastatic CCRCC patients can achieve desired outcomes with systemic therapies, and there is no significant difference in whether combined with surgical treatment (33).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review

Cao

Sun

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

BackgroundClear cell renal cell carcinoma (CCRCC) is a common urological neoplasm, and even though surgical resection is effective for localized CCRCC, the prognosis of metastatic CCRCC is poor. Currently, there is a paucity of recognized effective therapeutic protocols for metastatic CCRCC.Case presentationA 76-year-old Asian man underwent radical left nephrectomy for CCRCC 26 years ago; this patient visited our hospital with abdominal pain due to multiple abdominal metastases 24 years after the nephrectomy. After metastasectomy, he underwent targeted therapy combined with a programmed death receptor-1 (PD-1) inhibitor, and the current imaging results indicate remarkable tumor remission.ConclusionsMetachronous pancreatic metastasis from CCRCC after nephrectomy is rare, but clinicians and patients should not ignore this possibility. The combination of targeted therapy and immunotherapy can result in satisfactory outcomes in cases where metastatic CCRCC continues to progress despite metastasectomy and targeted therapy. The combination of local and systemic therapy can be an effective therapeutic protocol for metastatic CCRCC, but there is no consensus on suitable therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review

Cao

Sun

et al. 2022

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…Surgical resection is the main way of treatment [3] . However, more than 40% patients with RCC develop metastases after radical nephrectomy, and the 10-year cancer-speci c survival rate is dismal [2,4] . Unfortunately, there are no effective diagnostic biomarker and therapeutic target till now [5] .…”

Section: Introductionmentioning

confidence: 99%

Immunophenotyping analysis of renal cell carcinoma identified APOC1 as an immune-related biomarker and therapeutic target

Ren¹,

Jie²,

Wan³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Renal cell carcinoma (RCC), the most lethal common kidney cancer, accounts for 2–3% of all cancers in adults with no effective diagnostic biomarker and therapeutic target till now.Methods: In this study, the singularly expressed transcriptomics and immune infiltration phenotype of RCC had been clarified through systematic analysis of the RCC data set in TCGA. The abnormally expressed immune-related markers of RCC were analyzed via the above analysis. Using overexpression and knockdown assay, combined with migration, invasion, colony formation, cell cycle, immunohistochemistry, western blotting method experiments etc., the function and mechanism of immune-related marker were studied on RCC cell lines and nude mice.Results: Interestingly, we found that apolipoprotein C1 (APOC1) was dramatically overexpressed and correlated with RCC immunophenotype. The level of APOC1 in the serum of RCC patients was significantly increased with development of RCC and the expression level of APOC1 was related to the overall survival and disease-free survival of the patients. Knockdown of APOC1 expression inhibited the migration and invasion of RCC cells, which might be mediated by TGF-β, MMP3, and E-cadherin. Overexpression of APOC1 promoted the growth of RCC cells in medium, 3D Matrigel, and nude mice. Overexpression of APOC1 promoted the transition from G1 to S phase, while silencing of APOC1 arrested cycle of RCC cells at G2/M phase via FOXO1/P27/Cyclin D1 and P53/GADD45A/cdc2/Cyclin B1 pathway. Conclusions: Together, these data indicate that APOC1 was critical for mitotic progression, metastasis, and immune infiltration of RCC and may be an immune-related biomarker and therapeutic target for renal cell carcinoma.

show abstract

Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma

Christensen

Hajja

Koshkin

et al. 2021

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma

Cited by 5 publications

References 63 publications

Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review

Metastatic Clear Cell Renal Cell Carcinoma to Pancreas and Distant Organs 24 Years After Radical Nephrectomy: A Case Report and Literature Review

Immunophenotyping analysis of renal cell carcinoma identified APOC1 as an immune-related biomarker and therapeutic target

Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About